INHIBITION OF MACROPHAGE-SYNTHESIZED WNT7B TO INHIBIT TUMOR ANGIOGENESIS AND METASTASIS
The present invention provides methods of inhibiting angiogenesis in a malignant tumor, inhibiting metastasis of a malignant tumor and of inhibiting transformation of a benign tumor to a malignant tumor. The present invention also provides assays for identifying inhibitors of angiogenesis in a malignant tumor, inhibitors of metastasis of a malignant tumor and of inhibitors of transformation of a benign tumor to a malignant tumor.
1 . A method of inhibiting formation of blood vessels in a malignant tumor in a subject, or of inhibiting metastasis of a malignant tumor in a subject, comprising administering to the subject an inhibitor of Wnt7b in an amount effective to inhibit formation of blood vessels in a malignant tumor or metastasis of the malignant tumor in the subject, respectively.
2 . The method of claim 1 , wherein the inhibitor of Wnt7b is an inhibitor of macrophage-secreted Wnt7b or hematopoietic stroma-derived Wnt7b.
3 . The method of claim 1 , wherein the inhibitor of Wnt7b inhibits angiogenesis or vasculogenesis in the malignant tumor.
4 . The method of claim 1 , wherein inhibitor of Wnt7b inhibits metastasis of the malignant tumor.
5 . The method of claim 1 , wherein the malignant tumor is a tumor of the breast, prostate, lung, liver, cervix, pancreas, kidney, ovary, testicle, uterus, glia, central nervous system, oesphagus, stomach, colon, or is a glioblastoma, or wherein the metastasis is a pulmonary, bone, liver, breast, melanoma, kidney, cervix, or colon metastasis.
6 . The method of claim 1 , wherein the inhibitor of Wnt7b is an antibody which binds Wnt7b or a fragment of an antibody which fragment binds Wnt7b.
7 . The method of claim 6 , wherein the inhibitor of Wnt7b is a monoclonal antibody or a fragment of a monoclonal antibody.
8 . (canceled)
9 . The method of claim 1 , wherein the inhibitor of Wnt7b is an antisense which inhibits expression of Wnt7b.
10 . The method of claim 1 , wherein the inhibitor of Wnt7b is an siRNA which inhibits expression of Wnt7b or an shRNA which inhibits expression of Wnt7b.
11 . The method of claim 1 , wherein the inhibitor of Wnt7b is a small organic molecule of 2000 daltons or less.
12 - 13 . (canceled)
14 . A method of inhibiting a benign tumor from transforming into a malignant tumor in a subject comprising administering to the subject an inhibitor of Wnt7b in an amount effective to inhibit a benign tumor from transforming into a malignant tumor.
15 . The method of claim 14 , wherein the inhibitor of Wnt7b is an inhibitor of macrophage-secreted Wnt7b.
16 . (canceled)
17 . The method of claim 14 , wherein the inhibitor of Wnt7b is an antibody which binds Wnt7b or a fragment of an antibody which fragment binds Wnt7b.
18 . The method of claim 17 , wherein the inhibitor of Wnt7b is a monoclonal antibody or a fragment of a monoclonal antibody.
19 . (canceled)
20 . The method of claim 14 , wherein the inhibitor of Wnt7b is an antisense which inhibits expression of Wnt7b.
21 . The method of claim 14 , wherein the inhibitor of Wnt7b is an siRNA which inhibits expression of Wnt7b or an shRNA which inhibits expression of Wnt7b.
22 . The method of claim 14 , wherein the inhibitor of Wnt7b is a small organic molecule of 2000 daltons or less.
23 . The method of claim 22 , wherein the small organic molecule is pyrvinium(2-[(E)-2-(2,5-Dimethyl-1-phenylpyrrol-3-yl)ethenyl]-N,N,1-trimethylquinolin-1-ium-6-amine).
24 . The method of claim 14 , wherein the inhibitor is a secreted frizzled protein or an active fragment thereof.
25 . A method for identifying an agent as an inhibitor of angiogenesis and/or vasculogenesis in a malignant tumor or as an inhibitor of metastasis of a malignant tumor, comprising:
contacting an amount of Wnt7b with an amount of the agent and determining whether the agent inhibits the activity of the Wnt7b,
wherein if the agent inhibits the activity of the Wnt7b then the agent is an inhibitor of angiogenesis and/or vasculogenesis in a malignant tumor or an inhibitor of metastasis of a malignant tumor, and wherein if the agent does not inhibit the Wnt7b then the agent is not identified as an inhibitor of angiogenesis and/or vasculogenesis in a malignant tumor and/or an inhibitor of metastasis of a malignant tumor.
26 - 34 . (canceled)